Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053989 · ClinicalTrials.gov registry record · Phase 2
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00053989 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 41 participants.
The verdict
NCT00053989, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving immunosuppressive therapy before or after the transplant may stop this from happening. PURPOSE: This phase II trial is studying how well chemotherapy followed by donor peripheral stem cell transplant works in treating patients with hematologic cancer or aplastic anemia.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL sargramostim
- BIOLOGICAL therapeutic allogeneic lymphocytes
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2002-01-29 |
| Est. Completion | 2018-07-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053989
The ClinicalTrials.gov registry entry for NCT00053989 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00053989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00053989 about?
NCT00053989 is a clinical study titled "NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders". RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any...
What is the current status of trial NCT00053989?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2002-01-29. Estimated completion is 2018-07-19.
What interventions are being tested in trial NCT00053989?
The interventions under investigation include: cyclophosphamide (DRUG), anti-thymocyte globulin (BIOLOGICAL), sargramostim (BIOLOGICAL), therapeutic allogeneic lymphocytes (BIOLOGICAL), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00053989?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.